A rapid and simple LC-MS/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT)

被引:7
|
作者
Xiao, Yi [1 ]
Li, Xiaohan [2 ]
Fu, Xiaowei [1 ,3 ]
机构
[1] Childrens Hosp Los Angeles, Dept Pathol & Lab Med, 4650 Sunset Blvd MS 32, Los Angeles, CA 90027 USA
[2] China Med Univ, Shengjing Hosp, Dept Pathol, Shenyang 110004, Liaoning, Peoples R China
[3] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA
关键词
Busulfan; High performance liquid chromatography-mass spectrometry; BONE-MARROW-TRANSPLANTATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; HEPATIC VENOOCCLUSIVE DISEASE; INTRAVENOUS BUSULFAN; HUMAN-PLASMA; DECREASED INCIDENCE; MASS-SPECTROMETRY; DOSE ADJUSTMENT; ORAL BUSULFAN; PHARMACOKINETICS;
D O I
10.1016/j.cca.2018.01.020
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Busulfan is commonly used as a conditioning regimen before hematopoietic stem cell transplantation (HSCT). There is a big inter-individual variability in busulfan exposure and the narrow therapeutic index, especially in pediatric population. Therefore, to achieve therapeutic efficacy and safety concurrently, personalized busulfan dosing, guided by pharmacokinetic study with serial plasma samples, is needed a few hours afterwards. Methods: A fast, sensitive, and accurate method for busulfan measurement was developed, validated, and implemented with liquid-chromatography-mass spectrometry (HPLC-MS/MS). The sample preparation procedure involves only protein precipitation and dilution, and the HPLC MS/MS method takes 3 min/sample. The assay was linear from 10 ng/ml to 7500 ng/ml (R-2 = 0.99). Recoveries were above 90%. The precision was determined at 3 levels (30, 300 and 4000 ng/ml): the intra-day variability (%CV) ranged from 1.4% to 2.5% (n = 20); the inter-day variability ranged from 2.2% to 5.5% (n = 20). The accuracy of the HPLC MS/MS test was evaluated with an old HPLC-fluorescence method (n = 84), and a Correlation Coefficient (R) of 0.99 was observed. Conclusions: The analytical performance of the assay allows for timely dose adjustment and has been implemented in clinical service for better clinical outcome.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 50 条
  • [21] A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients
    Laverdiere, Isabelle
    Caron, Patrick
    Couture, Felix
    Levesque, Eric
    Guillemette, Chantal
    JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2012, 885 : 131 - 137
  • [22] Targeted LC-MS/MS-based metabolomics and lipidomics on limited hematopoietic stem cell numbers
    Schoenberger, Katharina
    Mitterer, Michael
    Buescher, Joerg M.
    Cabezas-Wallscheid, Nina
    STAR PROTOCOLS, 2022, 3 (02):
  • [23] Population Pharmacokinetics of Busulfan in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplant: A Model-Based Dosing Algorithm for Personalized Therapy and Implementation Into Routine Clinical Use
    Long-Boyle, Janel R.
    Savic, Rada
    Yan, Shirley
    Bartelink, Imke
    Musick, Lisa
    French, Deborah
    Law, Jason
    Horn, Biljana
    Cowan, Morton J.
    Dvorak, Christopher C.
    THERAPEUTIC DRUG MONITORING, 2015, 37 (02) : 236 - 245
  • [24] Development and validation of a simple, rapid and sensitive LC-MS/MS method for the measurement of urinary neurotransmitters and their metabolites
    Yan, Jingya
    Kuzhiumparambil, Unnikrishnan
    Bandodkar, Sushil
    Solowij, Nadia
    Fu, Shanlin
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2017, 409 (30) : 7191 - 7199
  • [25] Simple and Rapid LC-MS/MS Method for Determination of Perampanel in Human Plasma and Application to Bioequivalence Study
    Gao, Pan
    Zou, Qiao-gen
    CURRENT PHARMACEUTICAL ANALYSIS, 2022, 18 (10) : 919 - 929
  • [26] Development and validation of a simple, rapid and sensitive LC-MS/MS method for the measurement of urinary neurotransmitters and their metabolites
    Jingya Yan
    Unnikrishnan Kuzhiumparambil
    Sushil Bandodkar
    Nadia Solowij
    Shanlin Fu
    Analytical and Bioanalytical Chemistry, 2017, 409 : 7191 - 7199
  • [27] Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
    Michaud, Veronique
    Tran, My
    Pronovost, Benoit
    Bouchard, Philippe
    Bilodeau, Sarah
    Alain, Karine
    Vadnais, Barbara
    Franco, Martin
    Belanger, Francois
    Turgeon, Jacques
    PHARMACEUTICS, 2019, 11 (09)
  • [28] Significance of busulfan administration route including therapeutic drug monitoring in the conditioning regimen of pediatric patients prior to hematopoietic stem cell transplantation
    Haemmerle, Stephanie
    Ernst, Jana
    Steiner, Regula
    Guengoer, Tayfun
    Milde, Till
    Gruhn, Bernd
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2025, 151 (04)
  • [29] Predicting busulfan exposure in patients undergoing hematopoietic stem cell transplantation using machine learning techniques
    Li, Dandan
    Zhao, Jingtong
    Xu, Baohua
    Zheng, You
    Liu, Maobai
    Huang, Huiping
    Han, Song
    Wu, Xuemei
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (08) : 751 - 761
  • [30] Once-daily Intravenous Busulfan for 47 Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single Center Study
    Gonzalez-Vicent, Marta
    Molina, Blanca
    Perez, Antonio
    Angel Diaz, Miguel
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2012, 34 (03) : 180 - 183